1. Home
  2. ELDN vs NPV Comparison

ELDN vs NPV Comparison

Compare ELDN & NPV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELDN
  • NPV
  • Stock Information
  • Founded
  • ELDN 2004
  • NPV 1993
  • Country
  • ELDN United States
  • NPV United States
  • Employees
  • ELDN N/A
  • NPV N/A
  • Industry
  • ELDN Biotechnology: Pharmaceutical Preparations
  • NPV Investment Managers
  • Sector
  • ELDN Health Care
  • NPV Finance
  • Exchange
  • ELDN Nasdaq
  • NPV Nasdaq
  • Market Cap
  • ELDN 202.4M
  • NPV 199.1M
  • IPO Year
  • ELDN N/A
  • NPV N/A
  • Fundamental
  • Price
  • ELDN $2.63
  • NPV $11.09
  • Analyst Decision
  • ELDN Strong Buy
  • NPV
  • Analyst Count
  • ELDN 2
  • NPV 0
  • Target Price
  • ELDN $12.50
  • NPV N/A
  • AVG Volume (30 Days)
  • ELDN 1.0M
  • NPV 38.9K
  • Earning Date
  • ELDN 08-14-2025
  • NPV 01-01-0001
  • Dividend Yield
  • ELDN N/A
  • NPV 3.90%
  • EPS Growth
  • ELDN N/A
  • NPV N/A
  • EPS
  • ELDN 0.21
  • NPV N/A
  • Revenue
  • ELDN N/A
  • NPV N/A
  • Revenue This Year
  • ELDN N/A
  • NPV N/A
  • Revenue Next Year
  • ELDN N/A
  • NPV N/A
  • P/E Ratio
  • ELDN $12.40
  • NPV N/A
  • Revenue Growth
  • ELDN N/A
  • NPV N/A
  • 52 Week Low
  • ELDN $2.38
  • NPV $8.92
  • 52 Week High
  • ELDN $5.54
  • NPV $11.55
  • Technical
  • Relative Strength Index (RSI)
  • ELDN 36.28
  • NPV 54.21
  • Support Level
  • ELDN $2.54
  • NPV $10.95
  • Resistance Level
  • ELDN $2.82
  • NPV $11.12
  • Average True Range (ATR)
  • ELDN 0.21
  • NPV 0.07
  • MACD
  • ELDN -0.08
  • NPV 0.03
  • Stochastic Oscillator
  • ELDN 20.00
  • NPV 85.23

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

About NPV Nuveen Virginia Quality Municipal Income Fund

Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities.

Share on Social Networks: